Foley Partner David Rosen was quoted in an article that appeared in FDA Week on June 24, 2010 titled “OIG, Stakeholders Urge FDA To Clamp Down On Foreign Clinical Trials.” Rosen discusses criticisms directed towards the Food and Drug Administration (FDA) by lawmakers and drug safety advocates for what they view as lackluster oversight of clinical trials conducted abroad. He states that data collected during pivotal trials is likely to come under scrutiny by the FDA, adding that the majority of companies are working hard to ensure that data generated outside the U.S. is of very high quality.
People
Related News
December 12, 2025
In the News
Foley Chairman and CEO Daljit Doogal Talks Firm Strategy and Growth, Featured in Media for Reelection
Foley & Lardner LLP Chairman and CEO Daljit Doogal is featured in The American Lawyer article, “Foley Board Taps Daljit Doogal for Second Term as Chair and CEO,” for his reelection to a second four-year term.
December 11, 2025
In the News
Carrie Hoffman Comments on SCOTUS Arbitration Jurisdiction Case
Foley & Lardner LLP partner Carrie Hoffman commented on the U.S. Supreme Court's decision to hear an arbitration jurisdiction case in the Law360 article, "High Court Arb. Jurisdiction Case May Impact W&H Cases."
December 10, 2025
In the News
Charles Gass Quoted on Health Care Implications of Colorado AI Act
Foley & Lardner LLP senior counsel Charles Gass detailed Colorado's Artificial Intelligence Act and its implications for health providers in the ColoradoBiz article, “Colorado leads nation on AI healthcare regulations.”